Skip to main content
SearchLoginLogin or Signup

Review of "Health Impact and Cost-Effectiveness of Expanding Routine Immunization Coverage in India Through Intensified Mission Indradhanush: A Quasi-Experimental Study and Economic Evaluation"

Reviewers: D Shepard & S Zakir (Brandeis University) | πŸ“—πŸ“—πŸ“—πŸ“—β—»οΈ

Published onAug 09, 2024
Review of "Health Impact and Cost-Effectiveness of Expanding Routine Immunization Coverage in India Through Intensified Mission Indradhanush: A Quasi-Experimental Study and Economic Evaluation"
key-enterThis Pub is a Review of
Health impact and cost-effectiveness of expanding routine immunization coverage in India through Intensified Mission Indradhanush: a quasi-experimental study and economic evaluation
Health impact and cost-effectiveness of expanding routine immunization coverage in India through Intensified Mission Indradhanush: a quasi-experimental study and economic evaluation
Description

Abstract Background Many children do not receive a full schedule of childhood vaccines, yet there is limited evidence on the cost-effectiveness of strategies for improving vaccination coverage. We evaluated the cost-effectiveness of periodic intensification of routine immunization (PIRI), a widely applied strategy for increasing vaccination coverage.Methods Intensified Mission Indradhanush (IMI) was a large-scale PIRI intervention implemented in India in 2017–2018. In 40 sampled districts, we measured the incremental economic cost of IMI using primary data, and used a quasi-experimental impact evaluation to estimate incremental vaccination doses delivered. We estimated deaths and disability-adjusted life years (DALYs) averted using the Lives Saved Tool and reported cost-effectiveness from government provider and societal perspectives.Findings In sampled districts, IMI had an estimated incremental cost of 2021US$15.7 (95% uncertainty interval: 11.9 to 20.1) million from a provider perspective and increased vaccine delivery by an estimated 2.2 (βˆ’0.5 to 4.8) million doses, averting an estimated 1,413 (βˆ’350 to 3,129) deaths. The incremental cost was $7.14 per dose ($3.20 to dominated), $95.24 per zero-dose child reached ($45.48 to dominated), $375.98 ($168.54 to dominated) per DALY averted, $413.96 ($185.56 to dominated) per life-year saved, and $11,133 ($4,990 to dominated) per under-five death averted. At a cost-effectiveness threshold of 1x per-capita GDP per DALY averted, IMI was estimated to be cost-effective with 89% probability.Interpretation This evidence suggests IMI was both impactful and cost-effective for improving vaccination coverage. As vaccination programs expand coverage, unit costs may increase due to the higher costs of reaching currently unvaccinated children.Funding Bill & Melinda Gates Foundation

To read the original manuscript, click the link above.

Summary of Reviews: In 2014, the government of India launched a health campaign to increase coverage of routine immunizations. In this preprint, the authors evaluated the health impact and cost-effectiveness of this health campaign. The reviewers found this preprint reliable on the whole but suggested several areas for clarification in the manuscript.

Reviewer 1 (Donald S… & Shehreen Z…) | πŸ“—πŸ“—πŸ“—πŸ“—β—»οΈ

RR:C19 Strength of Evidence Scale Key

πŸ“• ◻️◻️◻️◻️ = Misleading

πŸ“™πŸ“™ ◻️◻️◻️ = Not Informative

πŸ“’πŸ“’πŸ“’ ◻️◻️ = Potentially Informative

πŸ“—πŸ“—πŸ“—πŸ“—β—»οΈ = Reliable

πŸ“˜πŸ“˜πŸ“˜πŸ“˜πŸ“˜ = Strong

To read the reviews, click the links below.Β 

Comments
2
?
will james:

The review suggests that expanding immunization coverage is both beneficial for public health and a worthwhile investment, supporting the continuation or expansion of the IMI program in India. https://handmlaw.net/

Marge Buker:

good info